Could the next major drug discovery come out of China? Goldman Sachs discusses

Goldman Sachs’ Ziyi breaks down why China is becoming the go-to market for early-stage drug development from cheaper, faster trials to an edge in engineering-driven ‘modalities’; even as the country works to deepen its global standing in innovative pharma.